Asprosin: A Novel Player in Metabolic Diseases

Frontiers in Endocrinology

Yan Zhu¹  Boyao Yu¹  Weidong Li¹  Mingyang Yuan¹  Jing Wu³ 

[1] Department of Endocrinology, Xiangya Hospital, Central South University, Changsha, China;Hunan Engineering Research Center for Obesity and Its Metabolic Complications, Changsha, China;National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China;

关键词: asprosin;    metabolic diseases;    diabetes;    obesity;    PCOS;    CVD;   

DOI  :  10.3389/fendo.2020.00064

来源: DOAJ

【 摘 要 】

Asprosin, a novel glucogenic adipokine, is encoded by two exons (exon 65 and exon 66) of the gene Fibrillin 1 (FBN1) and mainly synthesized and released by white adipose tissue during fasting. Asprosin plays a complex role in the central nervous system (CNS), peripheral tissues, and organs. It is involved in appetite, glucose metabolism, insulin resistance (IR), cell apoptosis, etc. In this review, we will summarize the newly discovered roles of asprosin in metabolic diseases including diabetes, obesity, polycystic ovarian syndrome (PCOS), and cardiovascular disease (CVD), which may contribute to future clinical diagnosis and treatment.

【 授权许可】

Unknown